FACULTY
James F. Howard Jr., MD
Professor of Neurology, Medicine & Allied Health
Department of Neurology–Neuromuscular Division
The University of North Carolina at Chapel Hill
Professor of Clinical Sciences (Neurology)
Department of Clinical Sciences (Neurology)
North Carolina State College of Veterinary Medicine
Raleigh, NC
Jeff Guptill, MD, MA, MHS
Professor of Neurology
Director, Duke Early Phase Clinical Research Unit
Duke Clinical Research Institute (DCRI)
Department of Neurology–Neuromuscular Medicine
Duke University School of Medicine
Durham, NC
PROGRAM OVERVIEW
This enduring activity focuses on the treatment and management of patients with generalized myasthenia gravis (gMG).
TARGET AUDIENCE
This activity is intended for neuromuscular, neuroimmunology, neuro-ophthalmology, general neurology, and advanced care practitioners such as nurse practitioners, doctors of pharmacy/registered pharmacists, and physician assistants involved in the management of patients with generalized MG.
LEARNING OBJECTIVES
On completing this program, attendees should be able to:
- Select appropriate treatments for patients with generalized MG based on their specific clinical characteristics
- Assess results from clinical trials evaluating emerging targeted therapies for the treatment of patients with generalized MG
- Predict the potential benefits of emerging targeted therapies for the treatment of generalized MG
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment and/or management of patients with generalized MG.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Guptill provided the following disclosures:
| Relationship | Manufacturer |
| Consultant | Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., argenx, Becton, Dickinson and Company (BD), Cabeletta Bio, Janssen Pharmaceuticals, Immunovant, Inc., Momenta Pharmaceuticals, Inc., Piedmont Pharmaceuticals, Ra Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Toleranzia, and UCB Pharma |
| Grant/research support: | Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, and NIH (NIAID, NINDS, NIHM) |
| Grant for fellowship training | UCB Pharma |
| Site investigator | Alexion, argenx, Janssen, Takeda Pharmaceutical Company, and UCB Pharma |
Dr. Howard provided the following disclosures:
| Relationship | Manufacturer |
| Advisory board member | Alexion Pharmaceuticals, Inc., argenx BVBA, Cartesian Therapeutics, Immunovant, Inc., Regeneron Pharmaceuticals, Inc., Sanofi USA, Toleraniza AB, Viela Bio, Inc. (now Horizon Therapeutics) |
| Site investigator | Alexion Pharmaceuticals, argenx BVBA, Millennium Pharmaceuticals, Inc., PCORI, Ra Pharmaceuticals (UCB), Centers for Disease Control and Prevention |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
- Andrew D. Bowser, ELS, CHCP, Medical Director for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
